1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the first-line treatment of stage III-IV follicular lymphoma

Technology appraisal guidance [TA243] Published date: 25 January 2012

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 Clinical need and practice
  • 3 The technology
  • 4 Evidence and interpretation
  • 5 Implementation
  • 6 Related NICE guidance
  • 7 Review of guidance
  • Appendix A: Appraisal Committee members and NICE project team
  • Appendix B: Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...
  • Download

Guidance

  • Next

6 Related NICE guidance

6 Related NICE guidance

  • Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma. NICE technology appraisal guidance 226 (2011).

  • Rituximab for the treatment of relapsed or refractory stage III of IV follicular non-Hodgkin's lymphoma (review of NICE technology appraisal guidance 37). NICE technology appraisal guidance 137 (2008).

  • Improving outcomes in haematological cancers – the manual. NICE cancer service guidance (2003).

  • National Institute for Health and Care Excellence (NICE)

  • Next